Recordati Industria Chimica e Farmaceutica S.p.A. (BIT: REC)
Health Care · Pharmaceuticals · IT
€52.85
-0.28% today · +1.4% 1Y
Recordati Industria Chimica e Farmaceutica S.p.A. (BIT: REC) operates in the Pharmaceuticals industry within the Health Care sector. The company is valued at $12.64B and employs 4,693 people.
Over the last twelve months the share price has gained 1.4%, trading between 43.76 and 55.15.
Tweenvest scores Recordati Industria Chimica e Farmaceutica S.p.A. across four factors: quality 86/100, value 84/100, growth 66/100, dividend 85/100. Its strongest factor is quality.
REC price history
Not enough price history to draw a chart yet.
Key figures
- Market cap
- $12.64B
- Revenue (TTM)
- $3.09B
- P/E
- 22.21
- EPS
- 2.38
- Dividend yield
- 2.53%
- Beta (5Y)
- 0.53
- 52-week high
- €55.15
- 52-week low
- €43.76
- Avg volume (3M)
- —
- Shares outstanding
- 204.81M
- Employees
- 4,693
- Next earnings
- —
About Recordati Industria Chimica e Farmaceutica S.p.A.
Recordati Industria Chimica e Farmaceutica S.p.A., together with its subsidiaries, researches, develops, produces, and sells pharmaceuticals in Italy, the United States, Spain, France, Germany, Russia, Ukraine, Turkey, Portugal, North Africa, and internationally. It operates through Specialty and Primary Care; and Rare Diseases segments. The company develops Maapliv for maple syrup urine disease; Isturia for endogenous Cushing’s syndrome; Cystadrops treatment of the ocular manifestations of cystinosis; Carbaglu for hyperammonemia due to n-acetyl glutamate synthase deficiency; Qarziba for neuroblastoma patients and patients with relapsed or refractory neuroblastoma; and Fotivda for renal cell carcinoma. It also develops Sylvant for idiopathic multicentric castleman diseases; Caphosol for oral mucositis; ENJAYMO for hemolysis in adults with cold agglutinin disease; Zanidip, Zanipress, Vazkepa, and Logimax for hypertension; Urorec and Avodart for symptoms of benign prostatic hyperplasia; and Livazo for dyslipidemia; Combodart/Duodart; Seloken for angina pectoris, myocardial infarction and cardiac rhythm disorders, as well as hypertension and functional heart disorders. In addition, the company offers Procto-Glyveno for internal and external hemorrhoids; Polydexa, Isofra, and Otofa for ear, nose and throat infections; Isturisa, for Cushing’s syndrome; Normosang, human hemin; Juxtapid, homozygous familial hypercholesterolemia;Ledaga, mycosis fungoides, T-cell cutaneous lymphoma;Tergynan, an anti-infective for gynecological infections; CitraFleet and Phosphosoda as bowel cleansers; Lomexin for gynecological and dermatological infections; Hexaspray, treatments for the oral cavity; Magnesio Supremo, a dietary supplement; Reaglia for schizophrenia; Eligard for hormone-dependent prostate cancer; and pasireotide in Phase II trial for patients with post-bariatric hypoglycemia, as well as other products. The company was founded in 1926 and is headquartered in Milan, Italy.
- ISIN
- IT0003828271
- Founded
- 1926
- Listed since
- Mar 24, 1995
- Exchange
- Borsa Italiana
- Currency
- EUR
Other Pharmaceuticals companies
| Company | Market cap | Price | Day |
|---|---|---|---|
| Eli Lilly and CompanyNYSE: LLY | $1.12T | $1,255.40 | +0.88% |
| Johnson & JohnsonNYSE: JNJ | $651.25B | $270.24 | +1.07% |
| Merck & Co., Inc.NYSE: MRK | $376.37B | $152.55 | +2.39% |
| Roche Holding AGSWX: ROP | $373.91B | CHF375.60 | +1.02% |
| Novartis AGSWX: NOVN | $302.17B | CHF127.42 | +0.85% |
| AstraZeneca PLCLSE: AZN | $258.76B | £122.40 | +1.26% |
| Novo Nordisk A/SCPSE: NOVO B | $207.84B | Dkr300.85 | +1.59% |
| Pfizer Inc.NYSE: PFE | $159.99B | $28.07 | +1.01% |
Figures last refreshed Aug 18, 2026.